Top

Drugs & Aging

Published in:

01-03-2018 | short communication

Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden

Authors: Ariel R. Green, Liza M. Reifler, Cynthia M. Boyd, Linda A. Weffald, Elizabeth A. Bayliss

Published in: Drugs & Aging | Issue 3/2018

Abstract

Background

Drugs with anticholinergic properties are considered potentially inappropriate in patients with cognitive impairment because harms—including delirium, falls, and fractures—may outweigh benefits.

Objective

To highlight opportunities to improve clinical decision making and care for patients with cognitive impairment and multiple chronic conditions, we identified distinct subgroups of patients with mild cognitive impairment (MCI) and dementia who had high cumulative anticholinergic burden and specific patterns of anticholinergic use.

Patients and Methods

We conducted a retrospective cohort study in a not-for-profit, integrated delivery system. Participants included community-dwelling adults aged 65 years and older (n = 13,627) with MCI or dementia and at least two other chronic diseases. We calculated the Anticholinergic Cognitive Burden (ACB) score for each participant from pharmacy and electronic health record (EHR) data. Among individuals with a mean 12-month ACB score ≥ 2, we used agglomerative hierarchical clustering to identify groups or clusters of individuals with similar anticholinergic prescription patterns.

Results

Twenty-four percent (3257 participants) had high anticholinergic burden, defined as an ACB score ≥ 2. Clinically meaningful clusters based upon anchoring medications or drug classes included a cluster of cardiovascular medications (n = 1497; 46%); two clusters of antidepressant medications (n = 633; 20%); and a cluster based on use of bladder antimuscarinics (n = 431; 13%). Several clusters comprised multiple central nervous system (CNS)-active drugs.

Conclusions

Cardiovascular and CNS-active medications comprise a substantial portion of anticholinergic burden in people with cognitive impairment and multiple chronic conditions. Antidepressants were highly prevalent. Clinical profiles elucidated by these clusters of anticholinergic medications can inform targeted approaches to care.

Available only for authorised users

Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83. https://doi.org/10.1212/wnl.0b013e31828726f5.CrossRefPubMedPubMedCentral

Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. JAMA Intern Med. 2015;175(3):408–9. https://doi.org/10.1001/jamainternmed.2014.7667.CrossRefPubMedPubMedCentral

Association Alzheimer’s. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;13(4):325–73. https://doi.org/10.1016/j.jalz.2017.02.001.CrossRef

Lin PJ, Zhong Y, Fillit HM, Chen E, Neumann PJ. Medicare expenditures of individuals with Alzheimer’s Disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc. 2016;64(8):1549–57. https://doi.org/10.1111/jgs.14227.CrossRefPubMed

Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. https://doi.org/10.1001/jama.294.6.716.CrossRefPubMed

Hinton L, Franz CE, Reddy G, Flores Y, Kravitz RL, Barker JC. Practice constraints, behavioral problems, and dementia care: primary care physicians’ perspectives. J Gen Intern Med. 2007;22(11):1487–92. https://doi.org/10.1007/s11606-007-0317-y.CrossRefPubMedPubMedCentral

Lin P-J, Zhong Y, Fillit HM, Chen E, Neumann PJ. Medicare expenditures of individuals with Alzheimer’s disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc. 2016;64(8):1549–57. https://doi.org/10.1111/jgs.14227.CrossRefPubMed

Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders. Alzheimers Dement. 2013;9(1):30–8. https://doi.org/10.1016/j.jalz.2012.11.002.CrossRefPubMed

Chatterjee S, Bali V, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Risk of mortality associated with anticholinergic use in elderly nursing home residents with depression. Drugs Aging. 2017. https://doi.org/10.1007/s40266-017-0475-5.PubMed

10.

Chatterjee S, Bali V, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Anticholinergic medication use and risk of fracture in elderly adults with depression. J Am Geriatr Soc. 2016;64(7):1492–7. https://doi.org/10.1111/jgs.14182.CrossRefPubMed

11.

American Geriatrics Society. Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46. https://doi.org/10.1111/jgs.13702.CrossRef

12.

Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. https://doi.org/10.1001/jamainternmed.2014.7663.CrossRefPubMedPubMedCentral

13.

Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455–9. https://doi.org/10.1136/bmj.38740.439664.de.CrossRefPubMedPubMedCentral

14.

Campbell NL, Unverzagt F, LaMantia MA, Khan BA, Boustani MA. Risk factors for the progression of mild cognitive impairment to dementia. Clin Geriatr Med. 2013;29(4):873–93. https://doi.org/10.1016/j.cger.2013.07.009.CrossRefPubMed

15.

Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMedPubMedCentral

16.

Agency for Healthcare Research and Quality. Chronic Condition Classification. http://www.icpsr.umich.edu/icpsrweb/content/AHRQMCC/shared-code.html. Accessed 14 August 2017.

17.

Amjad H, Carmichael D, Austin AM, Chang CH, Bynum JP. Continuity of Care and Health Care Utilization in Older Adults With Dementia in Fee-for-Service Medicare. JAMA Intern Med. 2016;176(9):1371–8. https://doi.org/10.1001/jamainternmed.2016.3553.CrossRefPubMedPubMedCentral

18.

Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the ‘Oldest Old’: a systematic review of the literature. Drugs Aging. 2015;32(10):835–48. https://doi.org/10.1007/s40266-015-0310-9.CrossRefPubMed

19.

Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63(1):85–90. https://doi.org/10.1111/jgs.13206.CrossRefPubMed

20.

Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75(2):152–9. https://doi.org/10.1212/wnl.0b013e3181e7f2ab.CrossRefPubMedPubMedCentral

21.

Campbell NL, Perkins AJ, Bradt P, Perk S, Wielage RC, Boustani MA, et al. Association of anticholinergic burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population. Pharmacotherapy. 2016;36(11):1123–31. https://doi.org/10.1002/phar.1843.CrossRefPubMedPubMedCentral

22.

Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9(6):434–41. https://doi.org/10.1016/j.amjopharm.2011.10.001.CrossRefPubMed

23.

Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27(12):987–97. https://doi.org/10.2165/11584430-000000000-00000.CrossRefPubMed

24.

Marengoni A, Rizzuto D, Wang HX, Winblad B, Fratiglioni L. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc. 2009;57(2):225–30. https://doi.org/10.1111/j.1532-5415.2008.02109.x.CrossRefPubMed

25.

Goldstein G, Luther JF, Jacoby AM, Haas GL, Gordon AJ. A taxonomy of medical comorbidity for veterans who are homeless. J Health Care Poor Underserved. 2008;19(3):991–1005. https://doi.org/10.1353/hpu.0.0040.CrossRefPubMed

26.

Newcomer SR, Steiner JF, Bayliss EA. Identifying subgroups of complex patients with cluster analysis. Am J Manag Care. 2011;17(8):e324–32.PubMed

27.

Shaukat A, Habib A, Lane KA, Shen C, Khan S, Hellman YM, et al. Anticholinergic medications: an additional contributor to cognitive impairment in the heart failure population? Drugs Aging. 2014;31(10):749–54. https://doi.org/10.1007/s40266-014-0204-2.CrossRefPubMed

28.

Parkinson L, Magin PJ, Thomson A, Byles JE, Caughey GE, Etherton-Beer C, et al. Anticholinergic burden in older women: not seeing the wood for the trees? Med J Aust. 2015;202(2):91–4.CrossRefPubMed

29.

Green AR, Oh E, Hilson L, Tian J, Boyd CM. Anticholinergic burden in older adults with mild cognitive impairment. J Am Geriatr Soc. 2016;64(12):e313–4. https://doi.org/10.1111/jgs.14554.CrossRefPubMedPubMedCentral

30.

Gerlach LB, Olfson M, Kales HC, Maust DT. Opioids and Other Central Nervous System-Active Polypharmacy in Older Adults in the United States. J Am Geriatr Soc. 2017. https://doi.org/10.1111/jgs.14930.PubMed

31.

Bhattacharjee S, Oh YM, Reiman EM, Burke WJ. Prevalence, Patterns, and Predictors of Depression Treatment among Community-Dwelling Elderly Individuals with Dementia in the United States. Am J Geriatr Psychiatry. 2017;25(7):803–13. https://doi.org/10.1016/j.jagp.2017.03.003.CrossRefPubMed

32.

Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry. 2012;27(12):1248–57. https://doi.org/10.1002/gps.3769.CrossRefPubMedPubMedCentral

33.

Orgeta V, Qazi A, Spector AE. Orrell M (2014) Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014;1:CD009125. https://doi.org/10.1002/14651858.cd009125.pub2.

34.

Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577–85. https://doi.org/10.1111/j.1532-5415.2011.03355.x.CrossRefPubMed

35.

Palmer JB, Albrecht JS, Park Y, Dutcher S, Rattinger GB, Simoni-Wastila L, et al. Use of drugs with anticholinergic properties among nursing home residents with dementia: a national analysis of Medicare beneficiaries from 2007 to 2008. Drugs Aging. 2015;32(1):79–86. https://doi.org/10.1007/s40266-014-0227-8.CrossRefPubMedPubMedCentral

36.

Kolanowski A, Fick DM, Campbell J, Litaker M, Boustani M. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc. 2009;10(4):252–7. https://doi.org/10.1016/j.jamda.2008.11.005.CrossRefPubMedPubMedCentral

37.

Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6. https://doi.org/10.1177/0091270006292126.CrossRefPubMed

38.

Sattler EL, Lee JS, Perri M 3rd. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30(6):383–99. https://doi.org/10.1007/s40266-013-0074-z.CrossRefPubMed

39.

Ostbye T, Taylor DH Jr, Clipp EC, Scoyoc LV, Plassman BL. Identification of dementia: agreement among national survey data, medicare claims, and death certificates. Health Serv Res. 2008;43(1 Pt 1):313–26. https://doi.org/10.1111/j.1475-6773.2007.00748.x.PubMedPubMedCentral

40.

Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A, Andrews G, et al. The prevalence of mild cognitive impairment in diverse geographical and Ethnocultural regions: the COSMIC collaboration. PLoS One. 2015;10(11):e0142388. https://doi.org/10.1371/journal.pone.0142388.CrossRefPubMedPubMedCentral

41.

Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement. 2012;8(1):14–21. https://doi.org/10.1016/j.jalz.2011.01.002.CrossRefPubMed

42.

Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177(1):51–8. https://doi.org/10.1001/jamainternmed.2016.6807.CrossRefPubMedPubMedCentral

43.

Matlow JN, Bronskill SE, Gruneir A, Bell CM, Stall NM, Herrmann N, et al. Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. J Am Geriatr Soc. 2017;65(7):1535–42. https://doi.org/10.1111/jgs.14844.CrossRefPubMed

44.

Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: the effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492–500. https://doi.org/10.1111/jgs.14034.CrossRefPubMedPubMedCentral

45.

Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, et al. Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med. 2011;155(5):300–8. https://doi.org/10.7326/0003-4819-155-5-201109060-00007.CrossRefPubMed

46.

Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W, et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging. 2013;30(9):655–66.CrossRefPubMedPubMedCentral

47.

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMed

Title: Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden
Authors: Ariel R. Green
Liza M. Reifler
Cynthia M. Boyd
Linda A. Weffald
Elizabeth A. Bayliss
Publication date: 01-03-2018
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 3/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-018-0522-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Older Patients’ Compliance with Drug Storage Recommendations

Relationship between Organizational Culture and the Use of Psychotropic Medicines in Nursing Homes: A Systematic Integrative Review

Do Risk Prediction Models for Postoperative Delirium Consider Patients’ Preoperative Medication Use?

Safety of Injectable HPβCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials

Prescription Changes During Geriatric Care Episodes: A Trend Analysis Conducted in Sweden

Author Correction to: Denosumab: A Review in Postmenopausal Osteoporosis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage